Clinical trial
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With…
NCT00019175 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00019175 |
|---|---|
| Title | Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma |
| Official title | PHASE I TRIAL IN PATIENTS WITH METASTATIC MELANOMA OF IMMUNIZATION WITH A RECOMBINANT FOWLPOX VIRUS ENCODING THE GP100 MELANOMA ANTIGEN |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | aldesleukin, fowlpox virus vaccine vector, gp100 antigen |
| Start date | Aug 1, 1996 |
| First posted | May 26, 2003 |
| Last update posted | Apr 29, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: